Shares of Teva Pharmaceutical Industries (TEVA -13.03%) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m. ET. The leg down comes as the S&P 500 (^GSPC -0.82%) and Nasdaq Composite (^IXIC -1.04%) lost 0.5% and 0.9%, respectively.
Teva reported earnings before trading began on Wednesday. The positive growth wasn't enough to outweigh guidance for 2025, which disappointed investors.
The pharma giant reported sales of $4.2 billion for Q4 and $16.5 billion for fiscal year 2024, up from 2023's revenue of $15.9 billion. The numbers slightly exceeded expectations, driven by better-than-expected sales of its lineup of drugs targeting migraines, Huntington's disease, and schizophrenia.
Its earnings per share (EPS) for Q4 was $0.71, down significantly from Q4 2023's $1.00, but slightly exceeding an expected $0.70.
The real issue came from its forecast EPS for 2025. The high end of the range the company offered -- $2.65 -- comes in well below the expected $2.76.
Teva is in the midst of what it calls its "Pivot to Growth strategy" and must continue to execute on its key components, notably its reorganization efforts to keep costs down, its focus on generics, and success in its research and development pipeline. The last of these initiatives comes with no guarantees of success, nor a clear timeline.
The company does, however, have some key drugs in later stages of trials, like its drug targeting ulcerative colitis and Crohn's disease. Though it looks promising, the company has its work cut out for it.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。